GreenLight Clinical will conduct Xintela’s First-in-Human clinical study on patients with knee osteoarthritis. Xintela, a Swedish biomedical company working in the field of regenerative medicine and cancer, focuses on new treatments for cartilage damage and brain tumours.
GreenLight Clinical’s CEO, Franz D´Lima said his team was “delighted to partner with Xintela. Our customised approach will enable Xintela to rapidly advance the XSTEM® program”
Xintela’s CEO, Evy Lundgren-Åkerlund noted both businesses had already “established a very close and productive working relationship, vital to Xintela’s next stage of clinical development of XSTEM®”
The clinical study starts in Australia in Q4, 2021. For more information about Xintela and the study, visit:
www.xintela.se/pressreleases/xintela-signs-with-australian-cro-for-clinical-study
Note: Knee Image on the News page is courtesy of freepik.com